We value your privacy

We use cookies to enhance your browsing experience, serve personalized content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies. Cookie Policy

Stock Unlock
Search global stocks & ETFs...Ctrl K
Learn Mode
DHR logo

DHR - Danaher Corp

226

$173.29

-$0.05 (-0.026%)
5/22/26, 2:31 PM
Stock Unlock LogoScore

3.71/5

General
Scores
Financials & KPIs
Dividends
Analyst
Insider
DHR
Valuation Score
View as %
Stock Unlock Logo
Stock Unlock
$160$244MayJulSepNovJanMar
1D
1W
1M
YTD
1Y
3Y
5Y
Max
Stock Profile
  • Market Cap
    $122.68B
  • Industry
    Life Sciences Tools & Services
  • EPS (TTM)
    $5.18
  • P/E (TTM)
    33.26
  • Div & Yield
    $1.60 (0.92%)
  • FCF Payout Ratio
    21.41%
  • P/S (TTM)
    4.95
  • P/B
    2.32
  • Diluted Shares
    711.20M
  • Ex-Dividend
    2026-06-26
  • Next Earnings
    07-20
  • Forward P/E
    20.25
  • Payout Ratio
    30.71%
  • P/FCF (TTM)
    23.19
  • FCF Yield
    4.31%
  • Earnings Yield
    3.01%
  • 52 Week Range
Score Card
Explore Scores Tab
3.71
Good
Danaher Corp has grown revenue at 4.02% over the past year, which suggests sales are increasing. Also, it has a free cash flow margin of 21.35%, which suggests the company is very profitable.
Valuation Model
Key Score
3.00
Average
Management
4.00
Good
Growth
5.00
Very Good
Profitability
3.00
Average
Fin. Health
1.00
Very Bad
Dividends
5.00
Very Good
Analyst
3.00
Average
Insider Transactions
Explore Insider Tab
Buy
Sell
20162017201820192020202120222023202420252026$0$150M$300M$450M$600M
Market News
Page 1 of 21
Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-19 17:10:11

Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-19 17:10:04

Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-19 17:09:58

Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-19 17:09:52

Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-19 17:09:46

Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-19 17:09:40

Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-19 17:09:36

Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-19 17:09:31

Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-19 17:09:26

Form SD
Specialized Disclosure Report

Filed on 2026-05-12 16:31:13

Form 8-K
Current report pursuant to Section 13 or 15(d)

Filed on 2026-05-07 16:36:15

Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-04 17:00:25

Page 1 of 21
Financials
Explore Financials Tab
Revenue
Earnings
Free Cash Flow
2022202320242025$0$7.00B$14B$21B$28B
Price Targets
Go to Analyst Tab
These are one year price targets for: 2027-05-11
High:
$325.50
87.8%
Avg:
$252.93
46.0%
Low:
$207.05
19.5%
(% change is relative to the current stock price: $173.29)
Analyst Recommendations
Go to Analyst Tab
4.20
Very Good
33%
Strong Buy (10)
53%
Buy (16)
13%
Hold (4)
0%
Sell (0)
0%
Strong Sell (0)
About
Company Logo
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. The firm operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
  • IPO Date
    1969-12-10
  • Industry
    Life Sciences Tools & Services
  • Total Employees
    58,000
  • Exchange
    New York Stock Exchange, Inc.
  • Reporting Currency
    USD
  • GICS
    Life Sciences Tools & Services
  • GICS Sub
    Life Sciences Tools & Services
  • GICS Sector
    Health Care
  • GICS Group
    Pharmaceuticals, Biotechnology & Life Sciences
Similar Stocks
Compare In Free Form
ILMN logo
ILMN
-0.02%
Illumina Inc
$144.80$21.4B
MTD logo
MTD
0.36%
Mettler-toledo International Inc
$1,094.42$21.2B
A logo
A
-0.24%
Agilent Technologies Inc
$114.51$31.2B
TMO logo
TMO
-0.20%
Thermo Fisher Scientific Inc
$448.45$166.4B
TEM logo
TEM
-0.95%
Tempus AI Inc
$46.05$8.2B
WAT logo
WAT
-0.09%
Waters Corp
$340.68$33.6B
WST logo
WST
-0.09%
West Pharmaceutical Services Inc
$315.83$19.1B
RVTY logo
RVTY
-0.10%
Revvity Inc
$95.29$10.7B
IQV logo
IQV
-1.76%
IQVIA Holdings Inc
$165.06$28.9B
MEDP logo
MEDP
-0.55%
Medpace Holdings Inc
$427.74$12.0B